Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A new method of detecting the C3b receptor is reported. A particular merit of this method is that anti-RBC rabbit antiserum is not required. Rosettes were formed with human B lymphocytes, B lymphoblasts and granulocytes, using sheep erythrocytes (SRBC) sensitized with fresh human serum (FHS). T lymphocytes and T lymphoblasts did not form rosettes. The percentage of cells forming rosettes with this method approximated the percentage of rosettes formed with EACm. However, FHS coated SRBC did not react with most cells of B cell type chronic lymphocytic leukemia (CLL), whereas EACm rosette formations showed a definite reaction. On the other hand, 34--58% of cells of chronic myelocytic leukemia (CML) bound with the indicator red cells. SRBC sensitized with fresh rabbit or guinea pig serum formed rosettes with PBL, tonsil cells, B lymphoblasts and granulocytes. Complement and IgM antibody were required for this reaction, as in EAC rosette formation.
 ...
PMID:Detection of human B cells and chronic myelocytic leukemic cells by rosette formation with sheep erythrocytes and fresh human sera. 31 33

The investigations, performed to study the possible mechanism of action of PTC, of its single constituents and of meta-levo-sarcolysin (m-L-SL) on the human immunocompetent system, are reported. The study entailed the evaluation of the effect of PTC, of its peptides and of m-L-SL on the various lymphocyte classes, employing all the more sophisticated immunological techniques such as: a) lymphocyte cultures stimulated with the various mitogens, (T and B lymphocytes); b) E rosettes (T lymphocytes); c) EA rosettes (lymphocytes with Fc receptors for IgG); d) EAC rosettes (lymphocytes with the C3 receptors); e) autoradiography and intracytoplasmic immunofluorescence (in vitro immunoglobulin neosynthesis); f) CdL (Complement-dependent Lymphocytotoxicity); g) LALI (Lymphocyte Antibody Lymphocytolytic Interaction); h) CML (antibody independent cytotoxicity i.e. Cell-Mediated Lympholysis). The evidence points out that the PTC effect on T and B lymphocytes is not comparable to that of m-L-SL which does not discriminate between the two lymphocyte populations while PTC, besides showing a scarce immunodepressive effect, preferentially affects B lymphocytes rather than T lymphocytes as shown also by the E rosette pattern. Significantly different appears also the influence of PTC, as compared with that of m-L-SL on the lymphocytes with Fc receptors for IgG (EA rosettes) and with receptors for the third component of complement (EAC rosettes) as well as on the cytotoxicity test and on the antibody dependent (LALI) and complement dependent (CdL) lytic effect. The data gleaned from this investigation allow evaluating both the effects of PTC on the immunocompetent system and the difference of its action from that of m-L-SL.
 ...
PMID:Effects of an antitumor multipeptide complex on immunocompetent and antigen-responsive cells. 108 83

A 42-year-old male with chronic myelogenous leukemia (CML) developed acute transformation associated with subcutaneous tumors. Histopathologic examinations of the tumors were done on two occasions; the first study revealed reticulum cell sarcoma-like features, and the second suggested a blastoma. Chromosomal analysis showed that the cells of the tumors originated from the CML clone. The cells had a negative reaction for myeloperoxidase by electron microscopy. Furthermore, biochemical and surface marker studies revealed that the tumor cells contained a significant terminal transferase activity. However, they did not express E- or EAC-rosette receptors, Ia-like antigens, or common ALL antigens.
 ...
PMID:Characterization of extramedullary tumors in a case of Ph-positive chronic myelogenous leukemia: possible involvement of immature T lymphocytes. 387 50

Leukemic cells from 32 patients were examined by using conventional immunological markers (E and EAC rosettes, surface immunoglobulins). Additionally, the test for intracytoplasmic IgM, Fc IgG receptor and the presence of light chains were performed. Leukemic blasts of all patients were investigated according to morphological and cytochemical criteria. Lymphoblasts from 3 patients had pre-B cell phenotype: cIgM +, sIg-. Each of 3 patients with pre-B cell characteristics had different diagnosis and different morphological and cytochemical features of the leukemic cells (ALL, NHL and CML). In 24 ALL cases the diagnosis of non-T, non-B ALL, in 4 cases T-ALL and in one B-ALL was established. The correlation of cytochemical results with special reference to acid phosphatase and immunological subclasses of ALL was also analyzed. An important question is raised with regard to diagnostic classification and treatment by finding ALL phenotypes in lymphoproliferative disorders that are not diagnosed as ALL.
 ...
PMID:Immunological typing of blast cells. Cases with pre-B cell characteristics. 620 92

Lymphocytes from 22 patients with chronic myeloid leukemia (CML), 13 treated with polychemotherapy, eight by monochemotherapy, and one untreated, were analyzed for the presence of classic T and B cell surface markers (E-rosette, EAC-rosette, surface immunoglobulins) and for their ability to respond to phytohemagglutinin (PHA). The absolute number and percentage of E-rosetting cells (T-cells), EAC-rosetting cells and cells staining for surface immunoglobulins (B cells) were all significantly lower than controls (P less than or equal to 0.025). The response to PHA was also significantly lower in patients than in controls at the smaller concentrations of the mitogen (3.75 micrograms/ml, 30 micrograms/ml) tested (P less than or equal to 0.01); at a higher PHA concentration (120 micrograms/ml) the decrease in PHA stimulation approached significance (P = 0.07). These lymphocyte abnormalities support the concept that CML lymphocytes may be derived from the leukemic clone.
 ...
PMID:Cell membrane markers and phytohemagglutinin reactivity of circulating lymphocytes from chronic myelocytic leukemia patients. 694 3

Normal and neoplastic human hematopoietic cells were examined for surface markers by a variety of techniques including cytotoxicity assays using anti-HTLA and anti-Ia antiserum with viability measured by trypan blue exclusion and automated flow cytometry; E- and EAC-rosette binding assays and surface immunoglobulin measured by a fluorescence-activated cell sorter. In most cases there was good agreement among these assays. However, one case of CLL of T origin (92% E-rosette-positive) also showed significant amounts of Ia antigen by cytotoxicity tests; additionally, a case of CML in blast crisis demonstrated no E or EAC markers or surface immunoglobulin, but the majority of cells were lysed by both anti-HTLA and anti-Ia antiserum. Thus, Ia is not an exclusive B cell marker.
 ...
PMID:Flow cytometric analysis of normal and neoplastic human hematopoietic surface antigens. 700 54

Here we describe the purification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from normal leukocytes of healthy subjects and leukocytes of chronic myeloid leukemia (CML) patients and from normal mouse muscle and sarcoma tissue. The data indicate that some properties of GAPDH of leukocytes of CML patients and sarcoma tissues are similar and also similar to those of EAC (Ehrlich ascites carcinoma) cellular GAPDH but distinctly different from those of the normal cellular GAPDH. Polyclonal antiserum raised against the 54 kDa subunit of EAC cell GAPDH strongly reacted with GAPDH of leukocytes of CML patients and sarcoma tissue GAPDH only and weakly reacted with GAPDH of normal leukocyte and normal muscle and a variety of other tissues of normal rats. Both the subunits of GAPDH of sarcoma tissues were partially sequenced from the N-terminus and compared with the known sequences of GAPDH. The altered properties of GAPDH of three different malignant sources might be common feature of all malignant cells, which is discussed in relation to glycolysis and malignant aberrations.
 ...
PMID:Molecular characterization of tumor associated glyceraldehyde-3-phosphate dehydrogenase. 1974 91